Metagenomi

pivot change turnaround direction walk away
Biotech

Metagenomi axes ALS program after seeing Biogen and Ionis flop

Metagenomi is seeking a partner for a program Moderna dropped and axing its amyotrophic lateral sclerosis activities in response to rivals' setbacks.
Nick Paul Taylor Aug 14, 2024 9:20am
empty stage microphone floor comedy spotlight

Moderna exits Metagenomi gene editing deal worth $3B biobucks

May 1, 2024 4:00pm
Photo of Wall Street street sign with american flags in the background

Metagenomi, Telomir offer double test case for preclinical IPOs

Feb 9, 2024 7:00am
Diverse group of hands holding up US dollar banknotes of various denominations on green background - stock photo

Kyverna raises IPO expectations to almost $300M

Feb 6, 2024 9:46am
Photo of Wall Street street sign with american flags in the background

Gene editing biotech Metagenomi plans modest $87M IPO

Feb 5, 2024 9:14am
IPO

Arrivent unveils $135M IPO pricing to get furmonertinib to FDA

Jan 22, 2024 10:28am